This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure. Mind Cure’s initial products are a branded line of organic mushroom nootropics.
Stock Performance
Mind Cure Health Inc. News 23 articles
- Mind Cure Health Inc. (To Be Renamed LNG Energy Group Corp.) Announces Completion of Business Combination Transaction
- Mind Cure Announces Closing of LNG Energy’s Subscription Receipt Financing
- Mind Cure Announces LNG Energy Group Credit Agreement in the Amount of U.S. $70 Million to Acquire Lewis Energy Colombia, Inc.
- Mind Cure and LNG Energy Group Provide Update on Previously Announced Business Combination Transaction
- Mind Cure Closes Previously Announced Private Placement
- MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH RESPECT TO PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION
- MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2023
- Mind Cure Enters Into Binding Letter of Intent with LNG Energy Group
- MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023 USA
- MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023
- MINDCURE Announces Financial Results for Fiscal 2022
- What’s Going On with MINDCURE?
- MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol through iSTRYM, MINDCURE’s Digital Therapeutics Platform
- MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
- MINDCURE Announces Financial Results for Fiscal 2021
- MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
- MINDCURE Announces Partnership with Speak Ai
- MINDCURE Files Provisional Patent Application For iSTRYM
- Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
- Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer
- Mind Cure Announces Geoff Belair as Chief Technology Officer
- Mind Cure Announces Commencement of Trading on the CSE
- Mind Cure Announces Closing of Oversubscribed Upsized Initial Public Offering